Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bio-Thera Solutions Expands Partnership with Avalon Pharma: Exclusive MENA Licensing Deal for Dupixent Biosimilar BAT2406 – Second Collaboration After BAT3306

Fineline Cube Aug 19, 2026
Company Deals

OmniAb Signs Global Collaboration and License Agreement with Eli Lilly for Ion Channel Program – Up to $370 Million in Milestones Plus Royalties

Fineline Cube Aug 18, 2026
Company Deals

Navi Therapeutics Completes Angel and Series A Rounds Totaling Several Hundred Million RMB – Legend Capital Co‑Leads Backing for Next‑Generation ADC Platform

Fineline Cube Aug 18, 2026
Company Deals

Ledeinno Medical Valley Closes Over 200 Million RMB in Series B+ and B++ Rounds – Shining Capital Leads Backing for Wireless SCS Neuromodulation Platform

Fineline Cube Aug 18, 2026
Company Deals

Enginprime Medical Closes Nearly 100 Million RMB Series A Round with Qiming Venture Partners as Sole Investor – Capital Earmarked for OpusOne pVAD Clinical Trials

Fineline Cube Aug 18, 2026
Policy / Regulatory

Trump Picks White House Policy Advisor Heidi Overton to Lead FDA – Replacing Acting Commissioner Kyle Diamantas After Makary’s Resignation

Fineline Cube Aug 19, 2026
Company Drug

Shanghai Yizhong Pharmaceutical’s YXC‑002 Wins IND Approval – Fourth‑Generation Brain‑Penetrant EGFR‑TKI for Non‑Small Cell Lung Cancer Overcomes C797S Resistance

Fineline Cube Aug 19, 2026
Company Drug

Genrix Bio’s GR2302 Bispecific Antibody Receives NMPA IND Approval for Chronic Hepatitis B – TCR‑Mimic T‑Cell Engager Targets HBV‑Infected Hepatocytes

Fineline Cube Aug 19, 2026
Company

BeiGene Reports 88% YOY Revenue Growth in Q3 2022

Fineline Cube Nov 10, 2022

China-based biotech BeiGene Inc. (HKG: 6160, SHA: 688235, NASDAQ: BGNE) released its Q3 2022 earnings...

Company Deals

Shandong Xinhua and Bayer Announce Strategic Partnership at CIIE

Fineline Cube Nov 9, 2022

A strategic partnership between China-based Shandong Xinhua Pharmaceutical Co., Ltd (HKG: 0719) and Bayer Consumer...

Company Deals

Medtronic Partners with Shanghai JiaHui Hospital at CIIE

Fineline Cube Nov 9, 2022

US-based Medtronic Inc. (NYSE: MDT) has announced a partnership with Shanghai JiaHui International Hospital, unveiled...

Company Deals

ChainGen Bio Raises RMB 45M in Angel Round for X-oligo Conjugates Development

Fineline Cube Nov 9, 2022

ChainGen Bio, a Shanghai-based developer of X-oligo conjugates (XOCs), has reportedly raised RMB 45 million...

Company Deals

Yibao Technology Secures Series A+ Funding to Expand Health Insurance Services

Fineline Cube Nov 9, 2022

Yibao Technology Co., Ltd, a Shanghai-based service provider for city-level supplementary commercial insurance (“Huiminbao”) schemes,...

Company Drug

Haisco’s HSK16149 Accepted for Review by NMPA for Diabetic Neuropathic Pain

Fineline Cube Nov 9, 2022

China-based Haisco Pharmaceutical Group Co., Ltd (SHE: 002653) has announced that a market approval filing...

Company Deals Digital

Cowell Health Partners with AstraZeneca to Enhance Cancer Care at CIIE

Fineline Cube Nov 9, 2022

Cowell Health has announced a partnership with UK-based AstraZeneca (AZ, NASDAQ: AZN) at the 5th...

Company Drug

Liaoning Chengda’s ACYW135 Meningococcal Vaccine Receives NMPA Clearance

Fineline Cube Nov 9, 2022

China’s Liaoning Chengda Biotechnology Co., Ltd (SHA: 688739) has announced that it has received clinical...

Company Drug

Zhaoke Ophthalmology Enrolls First Patients for ZKY001 in Phase II Trials

Fineline Cube Nov 9, 2022

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) spin-off Zhaoke Ophthalmology Ltd (HKG: 6622) has announced...

Policy / Regulatory

CDE Seeks Public Feedback on New Drug Benefit-Risk Assessment Guidelines

Fineline Cube Nov 9, 2022

The Center for Drug Evaluation (CDE) has released the “New Drug Benefit-Risk Assessment Technical Guidelines,”...

Company Deals

Zhaoke Ophthalmology Licenses C&V Tech’s TONO-i Tonometer for Greater China

Fineline Cube Nov 9, 2022

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) spin-off Zhaoke Ophthalmology Ltd (HKG: 6622) has announced...

Policy / Regulatory

CDE Releases Draft Guidelines on New Drug Benefit-Risk Assessment

Fineline Cube Nov 9, 2022

The Center for Drug Evaluation (CDE) has released the “New Drug Benefit-Risk Assessment Technical Guidelines,”...

Company Deals

Insilico Medicine Partners with Sanofi for AI-Driven Drug Discovery

Fineline Cube Nov 9, 2022

Insilico Medicine, an artificial intelligence (AI)-driven drug discovery company based in Hong Kong, has announced...

Policy / Regulatory

CDE Releases Guidelines on Pediatric Anti-tumor Drug Development

Fineline Cube Nov 9, 2022

The Center for Drug Evaluation (CDE) has released a Technical Guidelines document focused on “Clinical...

Company Deals

Pfizer Partners with CARD, CSAF, and PingAn Good Doctor at CIIE

Fineline Cube Nov 9, 2022

The 5th China International Import Expo (CIIE) saw the announcement of a partnership between US-based...

Company Deals

Pfizer China Partners with Alibaba Health for Disease Education at CIIE

Fineline Cube Nov 9, 2022

The 5th China International Import Expo (CIIE) saw US-based Pfizer’s China unit announce a partnership...

Company Deals

Adicon Partners with Illumina to Advance Oncology Detection Assay TSO 500

Fineline Cube Nov 9, 2022

China-based Adicon Holdings Limited has announced a strategic partnership with US-based Illumina (NASDAQ: ILMN) at...

Company Deals

Pfizer Partners with China Cardiovascular Association to Tackle Heart Failure

Fineline Cube Nov 9, 2022

US-based Pfizer (NYSE: PFE) has initiated a strategic partnership with the China Cardiovascular Association (CCA),...

Company Deals

Pfizer Partners with China Cardiovascular Association to Tackle Heart Failure

Fineline Cube Nov 9, 2022

US-based Pfizer (NYSE: PFE) has initiated a strategic partnership with the China Cardiovascular Association (CCA),...

Company Drug

MicuRx Pharmaceuticals Doses First Patient in China for MRX-8 Trial

Fineline Cube Nov 9, 2022

Shanghai-based antibacterial drug developer MicuRx Pharmaceuticals (SHA: 688373) has announced the first patient dosing in...

Posts pagination

1 … 647 648 649 … 710

Recent updates

  • Trump Picks White House Policy Advisor Heidi Overton to Lead FDA – Replacing Acting Commissioner Kyle Diamantas After Makary’s Resignation
  • Shanghai Yizhong Pharmaceutical’s YXC‑002 Wins IND Approval – Fourth‑Generation Brain‑Penetrant EGFR‑TKI for Non‑Small Cell Lung Cancer Overcomes C797S Resistance
  • Genrix Bio’s GR2302 Bispecific Antibody Receives NMPA IND Approval for Chronic Hepatitis B – TCR‑Mimic T‑Cell Engager Targets HBV‑Infected Hepatocytes
  • Novo Nordisk China Launches Organizational Restructuring – Merges Diabetes and Insulin Divisions into Hospital Business Division, Creates New Emerging Channels Division
  • Nhwa Pharmaceutical Wins NMPA IND Approval for Two Category 1 Chemical Drugs – NH130 for Schizophrenia & Alzheimer’s Psychosis, NH302 for Acute Pain
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Policy / Regulatory

Trump Picks White House Policy Advisor Heidi Overton to Lead FDA – Replacing Acting Commissioner Kyle Diamantas After Makary’s Resignation

Company Drug

Shanghai Yizhong Pharmaceutical’s YXC‑002 Wins IND Approval – Fourth‑Generation Brain‑Penetrant EGFR‑TKI for Non‑Small Cell Lung Cancer Overcomes C797S Resistance

Company Drug

Genrix Bio’s GR2302 Bispecific Antibody Receives NMPA IND Approval for Chronic Hepatitis B – TCR‑Mimic T‑Cell Engager Targets HBV‑Infected Hepatocytes

Company

Novo Nordisk China Launches Organizational Restructuring – Merges Diabetes and Insulin Divisions into Hospital Business Division, Creates New Emerging Channels Division

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.